Nicotine Metabolite Ratio As an Index of Cytochrome P450 2A6 Metabolic Activity
Overview
Authors
Affiliations
Background: Nicotine and a variety of other drugs and toxins are metabolized by cytochrome P450 (CYP) 2A6. Our objective was to evaluate the use of oral nicotine with measurement of the trans-3'-hydroxycotinine (3HC)/cotinine (COT) metabolite ratio as a noninvasive probe of CYP2A6 activity.
Methods: Sixty-two healthy volunteers received an oral solution of deuterium-labeled nicotine (2 mg) and its metabolite cotinine (10 mg). Plasma nicotine and plasma and saliva cotinine and 3HC concentrations were measured over time.
Results: The 3HC/COT ratio derived from deuterium-labeled cotinine, measured in either plasma (2-8 hours after administration) or saliva (at 6 hours), was strongly correlated with the oral clearance of nicotine (r = 0.76-0.83, depending on the time of measurement). The 6-hour 3HC/COT ratio from nicotine derived from tobacco in 14 smokers was highly correlated with the ratio derived from deuterium-labeled nicotine (r = 0.88) and was also highly correlated with the oral clearance of nicotine (r = 0.90). Two subjects homozygous for inactive CYP2A6 alleles produced no 3HC, confirming the specificity of the metabolite ratio. The 3HC/COT ratio was also highly correlated with the clearance and half-life of cotinine, consistent with the fact that cotinine is also primarily metabolized by CYP2A6.
Conclusions: The 3HC/COT ratio derived from nicotine either administered as a probe drug or from tobacco use, measured in either plasma or saliva, is highly correlated with the oral clearance of nicotine. The ratio appears to be a useful noninvasive marker of the rate of nicotine metabolism (which is important in studying nicotine addiction and smoking behavior), as well as a general marker of CYP2A6 activity (which is important in studying drug and toxin metabolism).
Wang N, Xiao W, Tang Q, Hu W, Wang S, Zhang Z Biomark Med. 2024; 18(23):1061-1073.
PMID: 39564794 PMC: 11633419. DOI: 10.1080/17520363.2024.2422809.
Zecic A, Vazdar B, Sliskovic L, Sutlovic D Arh Hig Rada Toksikol. 2024; 75(3):211-216.
PMID: 39369327 PMC: 11456220. DOI: 10.2478/aiht-2024-75-3846.
The hidden impact: the rate of nicotine metabolism and kidney health.
Wang X, Su S Front Endocrinol (Lausanne). 2024; 15:1424068.
PMID: 39355620 PMC: 11442274. DOI: 10.3389/fendo.2024.1424068.
Jansen K, Tranby B, Shane A, Takeno T, Chadwick K, Sinicrope P Arch Public Health. 2024; 82(1):129.
PMID: 39175017 PMC: 11340097. DOI: 10.1186/s13690-024-01365-7.
Langlois A, Chenoweth M, Twesigomwe D, Scantamburlo G, Whirl-Carrillo M, Sangkuhl K Clin Pharmacol Ther. 2024; 116(4):948-962.
PMID: 39051767 PMC: 11452280. DOI: 10.1002/cpt.3387.